Premenstrual syndrome has been dismissed by many doctors because their experiences have been limited to observations of their own cycles or those of their wives and female colleagues, most of whom experience only mild psychological symptoms with the ovarian endocrine cycle. Mild physiological symptoms occur in as many as 95% of women of reproductive age, only 5% being totally free from symptoms. Around 5% of symptomatic women complain of such severe symptoms that their lives are totally disrupted during the second half of the cycle. Symptoms may be so severe that they lead to suicide, parasuicide, and acts of violence against others.
The first step in helping women with premenstrual syndrome is for doctors to recognise the importance of the disorder and to distinguish true premenstrual syndrome from the milder and much commoner physiological symptoms. Women with premenstrual syndrome must also be distuinguished from women with a psychiatric disorder, whose symptoms are not related to the ovarian endocrine cycle. Failure to make these two distinctions has led to inappropriate and ineffective treatment.
Cause ofpremenstrual syndrome
No medical specialty has accepted responsibility for treating or conducting research into premenstrual syndrome. Little conclusive information exists on either aetiology or treatment. The current consensus is that normal ovarian function rather than hormone imbalance is the cyclical trigger for biochemical events within the central nervous system and other target tissues. A psychoneuroendocrine mechanism triggered by the normal endocrine events of the ovarian cycle seems the most plausible explanation. Logical approaches to treatment would therefore include modulation or removal of the ovarian steroid trigger or modulation or correction of neurotransmitter metabolism.
Both bilateral oophorectomyl and suppression of ovaries with analogues of gonadotrophin releasing hormone2 reliably cure premenstrual syndrome by eliminating the ovarian trigger, while serotonergic drugs treat premenstrual syndrome by modulating the neuroendocrine response to the ovary. Secondary premenstrual syndrome-The definition is similar to that of primary premenstrual syndrome. They are differentiated by the partial rather than complete resolution of symptoms after menstruation. Women often have underlying psychological problems as well as a cyclical disorder.
The nature of the symptoms of premenstrual syndrome is less important than the timing. The box lists some of the most characteristic symptoms. When evaluating patients it is important to determine the impact of menstruation on the symptoms and the effect the symptoms have on the patients' lives. Women should be asked to complete symptom charts daily for two months. Recording symptoms retrospectively is inaccurate and should not be used as a basis for treatment. 7 The advisory committee to the workshop group to revise the third edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-III), proposed the term late luteal phase dysphoric disorder, which refers only to the mood disturbance of premenstrual syndrome and excludes women who have symptoms throughout the luteal phase of the cycle. Premenstrual syndrome and luteal phase dysphoric disorder have wrongly been used interchangeably.
DIAGNOSTIC TESTS
It is sometimes difficult to distinguish which category a patient fits into. A formal psychiatric evaluation, including detailed analysis, structured interviews, and objective questionnaires may help to clarify the diagnosis in more difficult cases.
A gonadotrophin releasing hormone analogue test is often useful in women with severe symptoms in whom the diagnosis remains in doubt. Goserelin, a gonadotrophin releasing hormone agonist analogue, is given monthly for three months to eliminate cyclical ovarian function completely; the effect on symptoms is determined. Complete elimination of symptoms implies that the symptoms are solely dependent on ovarian activity, and the diagnosis is primary premenstrual syndrome. If symptoms continue into the third month an underlying psychiatric problem is present.
Various biochemical markers have been claimed to identify premenstrual syndrome. These include assays for thyroid hormones, cortisol, melatonin, platelet serotonin, progesterone, gonadotrophins, and sex hormone binding globulin. There is no evidence to support the use of any of these as a diagnostic test.4
Treating patients Some women can be helped very simply. Women with physiological premenstrual changes will benefit from counselling and reassurance and those with noncyclical psychiatric problems should be helped by early identification of their problem, with appropriate referral and therapy.
Treatment of women with very severe premenstrual syndrome is also relatively easy as it is easier to justify medical or surgical elimination of the menstrual cycle.
Patients with serious but less severe symptoms remain the most difficult to manage. Treatments that do not eliminate ovulation or ovarian fuction are unreliable. The response of patients is inconsistent and treatments are generally based on little credible scientific data.
Numerous treatments have been proposed over the past 60 years. This suggests that they are either ineffective or that the high placebo effect in premenstrual syndrome leads to overoptimistic conclusions being drawn.
Non-pharmacological methods
The pathogenesis of premenstrual syndrome is almost certainly more complex than the combination of ovarian activity and the resulting neurotransmitter changes. Many Relaxation and stress management can be included in formalised psychotherapy or taught through acupuncture, hypnosis, or yoga to suit the patient. 9 Such methods are difficult to evaluate precisely.
Exercise, vitamin therapy, and dietary change improve general health and self esteem and may increase women's tolerance to premenstrual change and thus reduce the impact of premenstrual syndrome.8 Although having regular carbohydrate meals to combat hypoglycaemia has been advocated enthusiastically, there is evidence that premenstrual "hypoglycaemia" is not related to low blood sugar levels and thus there is no justification for this approach. 10 Many specific dietary interventions have been suggested and include vitamins B-6 and A, magnesium, calcium, and evening primrose oil. The use of vitamin B-6, calcium, and magnesium has some logic as they are cofactors in neurotransmitter synthesis-for example, in the conversion of tryptophan to serotonin. There are studies to support and refute their efficacy.8 10 Evening primrose oil has been strongly promoted in recent years. Although there is good evidence that it relieves breast symptoms, studies on general premenstrual syndrome show only trends in favour of its use compared with placebo." 12 The studies were not large enough to achieve sufficient power to conclude that the treatment is ineffective. Since evening primrose oil has few side effects women should be allowed to self medicate, but it is expensive.
Non-hormonal drugs
Many non-hormonal drugs are used for the premenstrual syndrome, though few seem effective. Psychotropic drugs, particularly serotonin uptake inhibitors, have recently been shown to be helpful in women with exclusively premenstrual psychological disturbance and those with secondary premenstrual syndrome: fluoxetine and 
be helped by diuretics. When diuretics are necessary, the use of an aldosterone antagonist such as spironolactone should reduce the chances of developing idiopathic oedema.'1
Progesterone and progestogens
The widespread use of progesterone probably results from the enthusiasm of its advocacy rather than its pharmacotherapeutic efficacy.'6 Extensive anecdotal evidence has led to claims for efficacy by a few authors but randomised double blind placebo controlled trials do not support this view. '7 Only one study has shown that dydrogesterone is better than placebo in premenstrual syndrome, although it has been widely used since the 1970s. Cyclical medroxyprogesterone acetate and the depot preparation have reduced symptoms but only in limited trials.
Suppression ofthe endogenous cycle
If women do not respond to the less invasive treatments, the next step is to eliminate the ovarian trigger. There are several medical methods by which the endogenous ovarian or menstrual cycle could, in theory, be suppressed. These include combined oral contraceptives (cyclically or continuously), danazol, continuous progestogen, oestradiol patches, oestradiol implants, and gonadotrophin releasing hormone analogues (table) . Surgical methods will be discussed later.
ORAL CONTRACEPTIVE PILL
Cyclical combined oral contraceptives suppress ovulation but endocrine cyclicity remains. ' of this drug is limited by its perceived side effects, which have probably been overstated. Reversible masculinising side effects are a risk but these are rare. Masculinisation of a female fetus is also a risk if pregnancy should occur. If long term treatment is contemplated lipid levels should be monitored.
OESTROGEN PATCHES AND IMPLANTS
Initial reports of oestradiol implants showed sustained improvement when compared with placebo implants. These early studies also found no evidence of restimulation of the premenstrual syndrome symptoms during treatment with the cyclical progestogen. Although oestradiol implants have an important role in certain patients, long term use can cause problems. In a study of 50 women over two to eight years, new premenstrual syndrome symptoms developed in 58%.23 These symptoms can be managed by adjusting the type and dose of progestogen. Several patients (16%) had a hysterectomy, mainly because of progestogenic side effects and bleeding. There were no cases of thrombosis, pulmonary embolus, breast disease, or atypical endometrial hyperplasia. Sixty four per cent of the women also received a testosterone implant and it is not known what proportion of the improvement in symptoms was due to testosterone.
The effect of oestradiol patches has also been investigated in 40 women who received two 100 ,ug patches every third day.24 They also received cyclical norethisterone. Significant improvement in symptoms was shown compared with placebo.
Both oestradiol implants and patches have an important role in severely affected young patients and in many women who are approaching the menopause.
GONADOTROPHIN RELEASING HORMONE AGONIST ANALOGUES
These drugs can be given as nasal sprays, subcutaneous injections, and long acting depot preparations. They (fig 2) .25 Limited courses of gonadotrophin releasing hormone agonist analogues have several important indications. Firstly, in women whose psychological health and interpersonal relationships are deteriorating greatly six months free of symptoms can be invaluable, saving marriages and jobs. Secondly, the freedom from symptoms in the absence of the ovarian endocrine cycle shows the woman and her family that her problem has a biological basis. This is especially important when those around have considered this due to psychiatric or personality problems. Finally, in severely affected women who are to undergo hysterectomy for another gynaecological disorder the potential benefit of performing bilateral oophorectomy at the same time can be shown. Attempts have been made to protect the cardiovascular system and bone during long term treatment with gonadotrophin releasing hormone analogues by adding conventional hormone replacement therapy.2627 The protogestogens cause symptoms to recur in some women, but others experience continued relief. Tibolone may avoid such symptoms, but this has not been formally assessed.
Surgical approach
Surgery is rarely used to manage premenstrual syndrome (box). Symptoms persist after hysterectomy, though one study showed that symptoms were reduced without bilateral oophorectomy.29 This may be the result of the steroid changes which occur even when the ovaries are conserved. Total hysterectomy with bilateral salpingo-oophorectomy eliminates the symptoms of premenstrual syndrome.' Hypooestrogenic side effects can be prevented by unopposed oestrogen, without the need for cyclical progestogen. This is probably the only permanent cure for premenstrual syndrome but is appropriate for only a few severely affected women. The new popularity of endoscopic surgery has led to suggestions that premenstrual syndrome may be treated by laparoscopic oophorectomy. This is not feasible as oestrogen replacement will be required and the uterus will require cyclical progestogen therapy.
Although the results of one uncontrolled study support the use of endometrial ablation,30 logically this should not be effective because ovarian activity persists.
Choice oftreatment
The aim should be to provide the simplest and most effective treatment (fig 3) . Patients Severe premenstrual syndrome will, in practical terms, be defined as failure to respond to non-invasive methods. More aggressive methods will be needed for women who do not respond to the non-hormonal and non-surgical techniques.
Conclusions
Women with premenstrual syndrome can be helped. Our understanding of the problem has advanced greatly in the past few years but the final pathway in the aetiology still eludes us and there is no single, simple universal cure.
Mildly and moderately affected women can be managed with non-invasive techniques, and for severely affected patients elimination of the ovarian cycle by hormones or surgery can be justified. For women who fall between these extremes treatment is difficult and based on inadequate research.
In the long term if we are really to help women with premenstrual syndrome all doctors must be convinced of the importance of this problem. Only then will resources meet the current clinical needs. Research into premenstrual syndrome has been led almost entirely by the pharmaceutical industry. Virtually no funding has been provided for critical scientific research. And it is this, more than anything else, that will eventually enable us to treat premenstrual syndrome simply and effectively. THE CHALLENGE OF AIDS By September 1992 there were 6500 patients with AIDS but anything up to 60000 infected with HIV. Many of those with the virus are well, asymptomatic, and even unaware that they are infected, but others, although they have not yet developed AIDS, have physical, psychological, social, and occupational problems and require as much care as those with AIDS. We therefore need to be concerned not with "a few cases" but with a large number of people infected with a virus who will be making demands on every part of the health and social services. Not only are the numbers large but they will undoubtedly increase. New infections will occur, and the public health education campaign will need to continue.
The best we can hope for is a slowing down of the epidemic. None of us should feel that the problem of HIV infection and AIDS is unimportant and that it will go away because of the campaign and the possible magic bullet of a cure or vaccine.
